Gabriel Brooks sold $182k of SLDB
Chief Medical Officer at Solid Biosciences Inc.. 28,335 shares at an average of $6.44, traded Feb 2, 2026, filed Feb 2, 2026.
Score components
- +15RoleOfficer
- +12Trade size$182k at market
- +5Share of holdings soldSold 23% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-034083, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 29, 2026 | MOption exercise Common Stock10b5-1 | +58,847 | - | - | 96,818 | Feb 2, 2026 |
| Jan 31, 2026 | MOption exercise Common Stock10b5-1 | +28,225 | - | - | 125,043 | Feb 2, 2026 |
| Feb 2, 2026 | SOpen-market sale Common Stock10b5-1 | -28,335 | $6.44 | $182k | 96,708 | Feb 2, 2026 |
| Jan 29, 2026 | MOption exercise Performance Stock Unitsderivative10b5-1 | -58,847 | $0.00 | $0 | 0 | Feb 2, 2026 |
| Jan 29, 2026 | AGrant or award Employee Stock Option (Right to Buy)derivative10b5-1 | +207,450 | $0.00 | $0 | 207,450 | Feb 2, 2026 |
| Jan 29, 2026 | AGrant or award Restricted Stock Unitsderivative10b5-1 | +103,750 | $0.00 | $0 | 103,750 | Feb 2, 2026 |
| Jan 31, 2026 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -28,225 | $0.00 | $0 | 84,675 | Feb 2, 2026 |
Related signals
Other insiders at Solid Biosciences Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 8Weak | Solid Biosciences Inc. | Alexander Cumbo President and CEO | $97k 16,644 shares | -7% | |
| 17Weak | Solid Biosciences Inc. | Gabriel Brooks Chief Medical Officer | $81k 12,616 shares | -13% | |
| 32Weak | Solid Biosciences Inc. | Alexander Cumbo President and CEO | $315k 48,913 shares | -18% | |
| 21Weak | Solid Biosciences Inc. | Alexander Cumbo President and CEO | $517k 80,258 shares | -23% | |
| 17Weak | Solid Biosciences Inc. | Alexander Cumbo President and CEO | $55k 10,808 shares | -12% | |
| 0Weak | Solid Biosciences Inc. | Jessie Hanrahan Chief Regulatory Officer | $23k 4,483 shares | -14% | |
| 0Weak | Solid Biosciences Inc. | Paul Herzich Chief Technology Officer | $14k 2,701 shares | -9% | |
| 10Weak | Solid Biosciences Inc. | David T Howton Chief Operating Officer | $25k 4,932 shares | -13% | |
| 15Weak | SLDBsell Solid Biosciences Inc. | Ilan Ganot director | $14k 3,278 shares | -3% | |
| 0Weak | SLDBsell Solid Biosciences Inc. | Gabriel Brooks Chief Medical Officer | $17k 2,895 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.